Yan et al. found that gefitinib in combination with betulin (a natural ferroptosis inducer) is a novel therapeutic approach to overcome gefitinib resistance in EGFR wild-type/KRAS-mutant NSCLC cells by inducing ferroptosis in vitro and in vivo (Yan et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.